阿德福韦酯长期治疗对慢性乙型肝炎患者PBMCs中线粒体DNA的影响*

doi:10.3969/j.issn.1672-5069.2012.01.004

Abstract

Abstract: Objective To observe the changes of mitochondrial DNA levels in peripheral blood monouclear cells in patients with chronic hepatitis B receiving long-term adefovir treatment.Methods Patients with CHB were divided into three groups:（1） 2 years group（n=18）:receiving adefovir for 2 years;（2）3 years group（n=25）:adefovir for 3 years;and （3） control group（n=22）:naive patients without antiviral treatment.The mtDNA of PBMCs were detected by quantitative real-time PCR. Plasma MDA and F2-isoprostanes were measured by ELISA and TAOC were detected by spectrophotometry.Results The mtDNA in PBMCs in the 2-year treatment group was 0.6±0.4 copies/cell and in the 3-year treatment group was 0.8±0.5 copies/cell,both significantly lower than in the control group（1.4±1.2copies/cell,P<0.05）;the F2-isoprostanes in 2-year treatment group was 1.5±0.8 ng/ml and in 3-year treatment group was 2.2±1.3ng/ml,much lower than that in the control group（3.7±2.7 ng/ml,P<0.05）;the TAOC in 2-year treatment group was 3.0±1.1 IU/ml,and in 3-year treatment group was 2.3±1.4IU/ml, significantly lower than in the control group（4.3±1.8 IU/ml,P<0.05）.Conclusion The long-term administration of adefovir might injure mitochondrial DNA.

Key words: Hepatitis B, Adefovir, Peripheral blood monouclear cells, Mitochondria, Oxidative stress

Liu Xiaoyu, Zhou Li, Duan Zhongping, et al. The changes of mitochondrial DNA levels in peripheral blood monouclear cells in patients with chronic hepatitis b receiving long-term adefovir treatment[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(1): 10-13.

References

[1] Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology,2009, （5 Suppl）:S185-195.
[2] Lewis W,Day BJ,Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs:an integrated cellular perspective. Nat Rev Drug Discov,2003,2（10）:812-822.
[3] 王桂爽,蔡皓东. 阿德福韦酯和替诺福韦相关性肾小管病. 药物不良反应杂志,2010,12（1）:31-40.
[4] Tanji N,Tanji K,Kambhan N,et al. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol,2001,32（7）:734-740.
[5] Isnard-Bagnis C,Moulin B,Launay-Vacher V,et al. Anticancer drug-induced nephrotoxicity. Nephrol Ther,2005,1（2）:101-114.
[6] 吴焱,伦文辉, 闫会文,等. HAART相关症状性高乳酸血症的临床特征及影响因素分析. 中国艾滋病性病,2009,15（1）:4-8.
[7] Chiappini F,Teicher E,Saffroy R,et al. Relationship between polymerase gamma（POLG） polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients:a case-control study. Curr HIV Res,2009,7（2）:244-253.
[8] 吴荣荣,陈红鸽,刘淼,等. 替比夫定引起神经肌肉病变的临床观察. 中国新药杂志,2009,18（20）:2004-2008.
[9] Klusa V,Pupure J,Isajevs S,et al. Protection of azidothymidine-induced cardiopathology in mice by mildronate,a mitochondria-targeted drug. Basic Clin Pharmacol Toxicol,2006,99（4）:323-328.
[10] Arenas-Pinto A,Bhaskaran K,Dunnd D,et al. The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial. Antivir Ther,2008,13（2）:289-295.
[11] 吴亚松,陈新月,石英,等. HIV 感染和抗反转录病毒治疗对PBMC线粒体DNA含量影响. 北京医学,2010,32（6）:431-436.
[12] Chene G,Amellal B,Pedrono G,et al. Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy.AIDS Res Hum Retroviruses,2007,23（1）:54-61.
[13] 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案. 中华肝脏病杂志,2000,8:324-329.
[14] 张树林,吴宁强,梁雪松,等. HBV侵犯PBMC致线粒体功能改变. 世界华人消化杂志,1997,5（12）:783-784.
[15] Tan C,Guo H,Zheng M,et al. Involvement of mitochondrial permeability transition in hepatitis B virus replication. Virus Res,2009,145（2）:307-311.
[16] 林纳,李丹,陈红英,等. HBV X基因对成人肝细胞HL-7702线粒体功能的影响. 细胞与分子免疫学杂志,2008,24（10）:972-974.
[17] Stankov MV,Lucke T,Das AM,et al. Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors. Antimicrob Agents Chemother,2010,54（1）:280-287.
[18] De Mendoza C,De Ronde A,Smolders K,et al. Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. AIDS Res Hum Retroviruses,2004,20（3）:271-273.
[19] Timmermans EC,Tebas P,Ruiter JP,et al. Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy. Clin Chem,2006,52（6）:979-987.
[20] Wang CN,Chen JY,Sabu S,et al. Elevated amniotic fluid F2-isoprostane:a potential predictive marker for preeclampsia. Free Radic Biol Med,2011,50（9）:1124-1130.
[21] Hermsdorff HH,Puchau B,Volp AC,et al. Dietary total antioxidant capacity is inversely related to central adiposity as well as to metabolic and oxidative stress markers in healthy young adults. Nutr Metab （Lond,2011,8（1）:59.
[22] Long J,Wang X,Gao H,et al. Malonaldehyde acts as a mitochondrial toxin: inhibitory effects on respiratory function and enzyme activities in isolated rat liver mitochondria. Life Sci,2006,79（15）:1466-1472.
[23] Basu S. Radioimmunoassay of 8-iso-prostaglandin F2alpha:an index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids,1998,58（4）:319-325.
（校对：陈从新）

The changes of mitochondrial DNA levels in peripheral blood monouclear cells in patients with chronic hepatitis b receiving long-term adefovir treatment

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[14]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[15]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.